Skip to main content
Erschienen in: Hepatology International 2/2010

01.06.2010 | Original Article

Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans

verfasst von: Nghia H. Nguyen, Philip VuTien, Huy N. Trinh, Ruel T. Garcia, Long H. Nguyen, Huy A. Nguyen, Khanh K. Nguyen, Mindie H. Nguyen

Erschienen in: Hepatology International | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Although infection with hepatitis C virus (HCV) affects 32 million individuals from Southeast Asia, little is known about the mode of HCV acquisition and the epidemiology of chronic hepatitis C (CHC) in these individuals. Our goal was to examine risk factors for HCV acquisition, prevalence, and clinical characteristics of HCV genotype 6 compared with genotypes 1 and 2/3 in Southeast Asian (SEA) patients.

Methods

We performed a cross-sectional study of 308 consecutive SEA Americans with CHC evaluated by five gastroenterologists from January 2000 to December 2008 at two community clinics in northern California via medical record review, using a case report form.

Results

A significant proportion of patients (41%) could not recall any specific risk factors for HCV acquisition. The most commonly reported risk factor in patients who reported at least one risk factor was history of surgeries (34%), followed by blood transfusion (25%) and acupuncture (13%). Among patients with core sequence testing for HCV genotype (n = 181), the most common HCV genotypes were genotype 1 (42%) and genotype 6 (41%), followed by genotype 2/3 (17%). There were no major differences in the clinical and virological characteristics between the different genotype groups (1 vs. 2/3 vs. 6).

Conclusion

HCV genotype 6 is as common as genotype 1 in SEAs. Commonly known risk factors for HCV acquisition were not readily identifiable in a large proportion of SEA Americans (41%) and may not be useful in identifying at-risk individuals for HCV screening in this population.
Literatur
1.
Zurück zum Zitat Hepatitis C—global prevalence (update). Wkly Epidemiol Rec 1999;74(49):425–427 Hepatitis C—global prevalence (update). Wkly Epidemiol Rec 1999;74(49):425–427
2.
Zurück zum Zitat Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol 2008;103(1):131–137PubMed Mallette C, Flynn MA, Promrat K. Outcome of screening for hepatitis C virus infection based on risk factors. Am J Gastroenterol 2008;103(1):131–137PubMed
3.
Zurück zum Zitat El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36(5 Suppl 1):S74–S83CrossRefPubMed El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36(5 Suppl 1):S74–S83CrossRefPubMed
4.
Zurück zum Zitat Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002;35(3):266–269CrossRefPubMed Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002;35(3):266–269CrossRefPubMed
5.
Zurück zum Zitat Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705–714PubMed Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705–714PubMed
6.
Zurück zum Zitat Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005;9(3):411–426, viCrossRefPubMed Nguyen MH, Keeffe EB. Chronic hepatitis C: genotypes 4 to 9. Clin Liver Dis 2005;9(3):411–426, viCrossRefPubMed
7.
Zurück zum Zitat Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19(3):271–285CrossRefPubMed Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19(3):271–285CrossRefPubMed
8.
Zurück zum Zitat Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5–S16CrossRefPubMed Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1):S5–S16CrossRefPubMed
9.
10.
Zurück zum Zitat Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009;44(Suppl 19):102–107CrossRefPubMed Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol 2009;44(Suppl 19):102–107CrossRefPubMed
11.
Zurück zum Zitat Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147(10):677–684PubMed Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147(10):677–684PubMed
12.
Zurück zum Zitat Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1–39 Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47(RR-19):1–39
13.
Zurück zum Zitat Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004;141(9):715–717PubMed Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med 2004;141(9):715–717PubMed
14.
Zurück zum Zitat Li CP, Hwang SJ, Lu CL, Chan CY, Wu JC, Lee FY, et al. Risk factor analysis of patients with chronic hepatitis C in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 1996;58(4):275–280 Li CP, Hwang SJ, Lu CL, Chan CY, Wu JC, Lee FY, et al. Risk factor analysis of patients with chronic hepatitis C in Taiwan. Zhonghua Yi Xue Za Zhi (Taipei) 1996;58(4):275–280
15.
Zurück zum Zitat Ngo Y, Maugat S, Duong QT, Nguyen TN, Astagneau P. Risk of hepatitis C related to traditional medicine: a case control study in Ho Chi Minh City, Vietnam. Rev Epidemiol Sante Publ 2007;55(2):107–112 Ngo Y, Maugat S, Duong QT, Nguyen TN, Astagneau P. Risk of hepatitis C related to traditional medicine: a case control study in Ho Chi Minh City, Vietnam. Rev Epidemiol Sante Publ 2007;55(2):107–112
16.
Zurück zum Zitat Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006;101(12):2737–2743CrossRefPubMed Cheng JT, Hsien C, Sun HE, Tong MJ. The emerging importance of chronic hepatitis C infection in Asian Americans. Am J Gastroenterol 2006;101(12):2737–2743CrossRefPubMed
17.
Zurück zum Zitat Dev A, Sundararajan V, Sievert W. Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition. J Gastroenterol Hepatol 2004;19(7):792–798CrossRefPubMed Dev A, Sundararajan V, Sievert W. Ethnic and cultural determinants influence risk assessment for hepatitis C acquisition. J Gastroenterol Hepatol 2004;19(7):792–798CrossRefPubMed
18.
Zurück zum Zitat Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002;36(5):1259–1265CrossRefPubMed Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002;36(5):1259–1265CrossRefPubMed
19.
Zurück zum Zitat Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008;198(6):808–812CrossRefPubMed Fung J, Lai CL, Hung I, Young J, Cheng C, Wong D, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis 2008;198(6):808–812CrossRefPubMed
20.
Zurück zum Zitat Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003;187(7):1071–1074CrossRefPubMed Hui CK, Yuen MF, Sablon E, Chan AO, Wong BC, Lai CL. Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003;187(7):1071–1074CrossRefPubMed
21.
Zurück zum Zitat Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008;103(5):1131–1135CrossRefPubMed Nguyen MH, Trinh HN, Garcia R, Nguyen G, Lam KD, Keeffe EB. Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin. Am J Gastroenterol 2008;103(5):1131–1135CrossRefPubMed
22.
Zurück zum Zitat Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994;91(17):8239–8243CrossRefPubMed Bukh J, Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994;91(17):8239–8243CrossRefPubMed
23.
Zurück zum Zitat Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34(9):2259–2266PubMed Stuyver L, Wyseur A, van Arnhem W, Hernandez F, Maertens G. Second-generation line probe assay for hepatitis C virus genotyping. J Clin Microbiol 1996;34(9):2259–2266PubMed
24.
25.
Zurück zum Zitat Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(3 Suppl 1):122S–1227SCrossRefPubMed Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(3 Suppl 1):122S–1227SCrossRefPubMed
26.
Zurück zum Zitat Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22(4 Pt 1):1050–1056CrossRefPubMed Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22(4 Pt 1):1050–1056CrossRefPubMed
27.
Zurück zum Zitat McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21):1485–1492CrossRefPubMed McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339(21):1485–1492CrossRefPubMed
28.
Zurück zum Zitat Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426–1432CrossRefPubMed Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352(9138):1426–1432CrossRefPubMed
29.
Zurück zum Zitat Dunglison R. Medical Lexicon: a Dictionary of Medical Science. 15th ed. Philadelphia: Blanchard and Lea; 1857. 992 Dunglison R. Medical Lexicon: a Dictionary of Medical Science. 15th ed. Philadelphia: Blanchard and Lea; 1857. 992
30.
Zurück zum Zitat Nguyen V, McLaws M, Dore G. Prevalence and risk factors for hepatitis C infection in rural north Vietnam. Hepatol Int 2007;1(3):387–393 Nguyen V, McLaws M, Dore G. Prevalence and risk factors for hepatitis C infection in rural north Vietnam. Hepatol Int 2007;1(3):387–393
Metadaten
Titel
Risk factors, genotype 6 prevalence, and clinical characteristics of chronic hepatitis C in Southeast Asian Americans
verfasst von
Nghia H. Nguyen
Philip VuTien
Huy N. Trinh
Ruel T. Garcia
Long H. Nguyen
Huy A. Nguyen
Khanh K. Nguyen
Mindie H. Nguyen
Publikationsdatum
01.06.2010
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 2/2010
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-010-9181-7

Weitere Artikel der Ausgabe 2/2010

Hepatology International 2/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.